Technetium-99m dextran kit: formulation and biological behaviour

  • N. H. Agha
  • A. M. Al-hilli
  • N. D. Dahir
  • A. M. Al-nahhas


A new formulation of stannous-dextran (Sn-Dx) freeze dried kit, containing 60 mg dextran (Dx-70) and 0.08 mg SnCl2·2H2O, to be labelled with99mTc, has been developed. At pH 6.5–7.0. the labelling efficiency was greater than 95%. Gel chromatography column scanning technique was applied for radiochemical purity determination of99mTc-Dx preparation and the degree of in vivo plasma protein binding. Not less than 70% of the administered activity was bound to plasma and remained constant over a 1h period. The biological behaviour after intravenous injection of99mTc-Dx kit was characterized by high and efficient yield of the radiopharmaceutical. The preliminarly clinical results on normal subjects showed that the radiopharmaceutical could be a useful agent for scintigraphy of leg lymph vesel, pelvic and inguinal lymph nodes. The activity uptake in liver and kidney (60 min) was relatively very low, whereas the urinal bladder activity (30 min) represents the drainage of the activity entering the blood stream after interdigital injection of99mTc-Dx.


Dextran Urinal Bladder Biological Behaviour SnCl2 Plasma Protein Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J. W. WALKEY, J. B. TILLMAN, J. Pharm, Pharmac, 28 (1979) 29.Google Scholar
  2. 2.
    E. HENZE, G. D. ROBINSON, H. R. SCHELBERT, D. E. KUHL, J. Nucl. Med., 23 (1982) 348.PubMedGoogle Scholar
  3. 3.
    K. ASPERGEN, S. E. STRAND, B. R. R. PERSSON, Acta. Radiol. Oncol., 17 (1978) 17.Google Scholar
  4. 4.
    S. E. STRAND, B. R. R. PERSSON, J. Nucl. Med., 20 (1979) 1038.PubMedGoogle Scholar
  5. 5.
    W. D. KAPLAN, M. A. DAVIS, C. M. ROSE, J. Nucl. Med., 20 (1979) 933.PubMedGoogle Scholar
  6. 6.
    G. N. EGE, Radiology 118 (1976) 101.PubMedGoogle Scholar
  7. 7.
    E. HENZE, H. R. SCHELBERT, J. D. COLLINS, A. NAJAFI, J. R. BARRIO, L. R. BENNETT, J. Nucl. Med., 23 (1982) 923.PubMedGoogle Scholar
  8. 8.
    B. R. R. PERSSON, Gel-chromatography column-scanning (GCS). A method for identification and quality control of99mTc-radiopharmaceuticals, In: Proc. Int. Symp. Radiopharmaceutials, 1974, Atlanta, Ga., USA. Soc. Nucl. Med. (N. Y.) 1975, p. 228.Google Scholar
  9. 9.
    W. DeKIEVIET, J. Nucl. Med., 22 (1981) 703.PubMedGoogle Scholar
  10. 10.
    C. D. RUSSEL, A. G. SPESIOR, J. Nucl. Med., 21 (1980) 1080.PubMedGoogle Scholar
  11. 11.
    W. DeKIEVIET, J. Labell. Comp. Raiopharm., 18 (1981) 136.Google Scholar
  12. 12.
    A. WADE (Ed.), Martindale — The Extra Pharmacopoeia: Dextrans, The Pharmaceutical Press, London 1977, p. 461.Google Scholar

Copyright information

© Akadémiai Kiadó 1989

Authors and Affiliations

  • N. H. Agha
    • 1
  • A. M. Al-hilli
    • 1
  • N. D. Dahir
    • 1
  • A. M. Al-nahhas
    • 1
  1. 1.Radioizotope Production DepartmentNuclear Research CentreBaghdad(Iraq)

Personalised recommendations